EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Open Access

Safety, pharmacokinetics, and potential benefits of TSH-receptor-specific monoclonal autoantibody K1-70TM in Japanese Graves’ disease patients: results of a phase 1 trial

Jaeduk Yoshimura Noh, Natsuko Watanabe, Koichi Ito, Mika Tsuiki, Yuki Ishihara, Tetsuya Tagami, Ichiro Yamauchi, Ai Kozaki, Toshu Inoue, Bernard Rees Smith

Endocrine Journal · 2025 · 72 (8) · 897-909

DOI: 10.1507/endocrj.ej25-0043 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Endocrine Journal, 2025. Verfasst von Jaeduk Yoshimura Noh und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Ito Hospital, Tokyo, Japan. Hauptthemen laut MEDLINE: Graves Disease, Receptors, Thyrotropin, Autoantibodies, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Nippon Smith Yakuhin Kabushiki Kaisha.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This phase 1 dose-escalation study evaluated the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of K1-70TM, a TSH-receptor-specific monoclonal autoantibody that inhibits ligand binding and receptor activation, in Japanese Graves' disease (GD) patients. Twelve patients were enrolled, divided into four dosage cohorts (5 mg, 25 mg, 75 mg, and 150 mg), and monitored for 100 days post-administration. The primary objective was to assess safety and tolerability, and the secondary objectives were evaluation of PK and thyroid function. Exploratory analyses focused on the dynamics of the anti-TSH receptor antibodies and Thyroid eye disease (TED). K1-70TM demonstrated a favorable safety profile, with no reports of serious adverse events. Mild to moderate treatment-emergent adverse events, such as headache and fatigue, were observed in 83.3% of the participants, but none were deemed severe. PK analysis revealed a dose-dependent increase in half-life, suggesting prolonged systemic exposure at higher doses. Thyroid function remained stable at lower doses, but there were dose-dependent reductions at higher doses that were managed with adjunctive L-thyroxine therapy. Marked reductions in TSAb levels were observed across all cohorts, indicating effective suppression of TSH receptor activity. An improvement in proptosis was noted in 50% of the eyes, suggesting a potential therapeutic benefit against inactive-phase TED. These findings support K1-70TM as a promising targeted therapy for GD and TED, and they warrant further studies involving larger patient populations and active disease phases to confirm its efficacy and safety (jRCT Registration Number: JRCT2080224902).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Graves DiseaseReceptors, ThyrotropinAutoantibodiesAntibodies, Monoclonal, HumanizedAntibodies, MonoclonalHumansMaleFemaleAdultMiddle AgedJapanDose-Response Relationship, DrugAgedTreatment OutcomeEast Asian People

Stichwörter der Autor:innen

Graves’ diseaseGraves’ ophthalmopathyK1-70TMPharmacokineticsSafety profile

Substanzen

Receptors, ThyrotropinAutoantibodiesAntibodies, Monoclonal, HumanizedteprotumumabAntibodies, Monoclonal

Autor:innen und Institutionen

  • Department of Internal Medicine, Ito Hospital, Tokyo, Japan.
  • Department of Endocrinology and Metabolism, and Clinical Research Institute for Endocrine and Metabolic Diseases, National Hospital Organization Kyoto Medical Center, Kyoto, Japan.
  • Department of Diabetes, Endocrinology and Nutrition, Kyoto University Graduate School of Medicine, Kyoto University, Kyoto, Japan.
  • Olympia Eye Hospital, Tokyo, Japan.
  • Nippon Smith Yakuhin Kabushiki Kaisha, Tokyo, Japan.
  • RSR Limited, FIRS Laboratories, Parc Ty Glas, Cardiff, UK.

Förderung

  • Nippon Smith Yakuhin Kabushiki Kaisha

Zitieren

APA

Noh, J. Y., Watanabe, N., Ito, K., Tsuiki, M., Ishihara, Y., Tagami, T., Yamauchi, I., Kozaki, A., Inoue, T., & Smith, B. R. (2025). Safety, pharmacokinetics, and potential benefits of TSH-receptor-specific monoclonal autoantibody K1-70TM in Japanese Graves’ disease patients: results of a phase 1 trial. Endocrine Journal, 72(8), 897-909. https://doi.org/10.1507/endocrj.ej25-0043

Vancouver

Noh JY, Watanabe N, Ito K, Tsuiki M, Ishihara Y, Tagami T, et al. Safety, pharmacokinetics, and potential benefits of TSH-receptor-specific monoclonal autoantibody K1-70TM in Japanese Graves’ disease patients: results of a phase 1 trial. Endocrine Journal. 2025;72(8):897-909. doi:10.1507/endocrj.ej25-0043

BibTeX
@article{Noh2025,
  author = {Noh, Jaeduk Yoshimura and Watanabe, Natsuko and Ito, Koichi and Tsuiki, Mika and Ishihara, Yuki and Tagami, Tetsuya and Yamauchi, Ichiro and Kozaki, Ai and Inoue, Toshu and Smith, Bernard Rees},
  title = {Safety, pharmacokinetics, and potential benefits of TSH-receptor-specific monoclonal autoantibody K1-70TM in Japanese Graves’ disease patients: results of a phase 1 trial},
  journal = {Endocrine Journal},
  year = {2025},
  volume = {72},
  number = {8},
  pages = {897--909},
  doi = {10.1507/endocrj.ej25-0043}
}
Kostenlos starten →